CIViC Evidence Items

265 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline

BClinical — prospective trial or retrospective cohort study

CCase study — single case report or small case series

DPreclinical — in vitro or animal model data

EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

	Predictive	Diagnostic	Prognostic	Functional	Predispos.	Oncogenic
BCR::ABL1	323	11
BRAF	186	4	26	2		1
EGFR	248		12	3		2
EML4::ALK	64
ERBB2	142		2
FLT3	55	2	21
KIT	102	3	7
KRAS	159	4	24			4
PIK3CA	156		16	4
PTEN	53	1	3	1	2	1
TP53	52		40	100	2
VHL	5	2	3		635	15

Predictive:Links a variant to treatment response or resistance

Diagnostic:Supports or refutes a specific disease diagnosis

Prognostic:Informs disease progression or clinical outcome

Functional:Characterises the biological effect of a variant

Predisposing:Germline variant associated with cancer predisposition

Oncogenic:Characterises the variant's role in oncogenesis

Level	Gene	Variant	Type	Direction	Significance	Disease	Drugs	Source
A	EGFR	T790M	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Erlotinib	Denis et al., 2015
D	EGFR	T790M	Predictive	Supports	Resistance	Lung Cancer	Multikinase Inhibitor AEE788,Gefitinib	Yun et al., 2008
A	EGFR	T790M	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Osimertinib	Greig, 2016
A	EGFR	T790M	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Osimertinib	Mok et al., 2017
B	EGFR	Mutation	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib	Mitsudomi et al., 2010
B	EGFR	Mutation	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib	Mok et al., 2009
A	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib	Khozin et al., 2014
A	EGFR	Exon 19 Deletion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib	Khozin et al., 2014
A	EGFR	Exon 19 Deletion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Afatinib	Dungo et al., 2013
A	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Afatinib	Dungo et al., 2013
B	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Dacomitinib	Ramalingam et al., 2016
A	EGFR	L858R OR EGFR Exon 19 Deletion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Osimertinib	Wu et al., 2020
A	EGFR	L858R OR EGFR Exon 19 Deletion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Dacomitinib	Wu et al., 2017
A	EGFR	L858R OR EGFR Exon 19 Deletion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib,Ramucirumab	Nakagawa et al., 2019
A	EGFR	L858R OR EGFR Exon 19 Deletion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Osimertinib,Chemotherapy	Planchard et al., 2023
B	EGFR	T790M	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Dacomitinib	Sequist et al., 2011
D	EGFR	Exon 19 Deletion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib	Ji et al., 2006
D	EGFR	G719S	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib	Paez et al., 2004
B	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	Fukihara et al., 2014
D	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib	Paez et al., 2004
B	EGFR	T790M	Prognostic	Supports	Poor Outcome	Lung Non-small Cell Carcinoma		Ding et al., 2014
B	EGFR	T790M	Prognostic	Supports	Poor Outcome	Lung Non-small Cell Carcinoma		Li et al., 2014
B	EGFR	Exon 19 Deletion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib,Erlotinib	Jackman et al., 2006
B	EGFR	Copy Number Variation	Prognostic	Supports	Poor Outcome	Head And Neck Squamous Cell Carcinoma		Temam et al., 2007
B	EGFR	Amplification	Prognostic	Supports	Poor Outcome	Head And Neck Squamous Cell Carcinoma		Chung et al., 2006
B	EGFR	T790M	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Rociletinib	Sequist et al., 2015
D	EGFR	Exon 4 Deletion	Predictive	Supports	Resistance	Epithelial Ovarian Cancer	Cisplatin	Zhang et al., 2013
B	EGFR	Amplification	Predictive	Does Not Support	Sensitivity/Response	Head And Neck Squamous Cell Carcinoma	Cetuximab,Platinum Compound,Fluorouracil	Licitra et al., 2011
B	EGFR	Overexpression	Predictive	Does Not Support	Sensitivity/Response	Head And Neck Squamous Cell Carcinoma	Cetuximab	Licitra et al., 2013
B	EGFR	Overexpression	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Pirker et al., 2012
C	EGFR	S492R	Predictive	Supports	Resistance	Colorectal Cancer	Cetuximab	Montagut et al., 2012
B	EGFR	VIII	Predictive	Supports	Sensitivity/Response	Glioblastoma	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Mellinghoff et al., 2005
D	EGFR	G724S	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Cetuximab	Cho et al., 2014
D	EGFR	G719S	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Cetuximab	Cho et al., 2014
B	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Afatinib	Sequist et al., 2013
B	EGFR	Exon 19 Deletion	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Afatinib	Sequist et al., 2013
B	EGFR	Amplification	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Dahabreh et al., 2011
B	EGFR	T790M	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Osimertinib	Jänne et al., 2015
B	EGFR	Exon 19 Deletion	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Afatinib	Wu et al., 2014
B	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Afatinib	Wu et al., 2014
B	EGFR	Exon 19 Deletion	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Afatinib	Yang et al., 2015
C	EGFR	G465R	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Futuximab/Modotuximab Mixture	Sánchez-Martín et al., 2016
C	EGFR	G465R	Predictive	Supports	Resistance	Colorectal Cancer	Cetuximab,Panitumumab	Sánchez-Martín et al., 2016
D	EGFR	S492R	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Panitumumab,Futuximab/Modotuximab Mixture	Sánchez-Martín et al., 2016
D	EGFR	S492R	Predictive	Supports	Resistance	Colorectal Cancer	Cetuximab	Sánchez-Martín et al., 2016
B	EGFR	Expression	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Cetuximab	Jonker et al., 2007
B	EGFR	Mutation	Prognostic	Supports	Better Outcome	Lung Adenocarcinoma		Johnson et al., 2013
B	EGFR	Mutation	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Afatinib	Park et al., 2016
B	EGFR	T790M	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Afatinib	Sun et al., 2013
B	EGFR	Mutation	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	Ludovini et al., 2011

Page 1 of 6